Takeda’s Experimental Bowel Drug Effective, Studies Find
This article is for subscribers only.
Takeda Pharmaceutical Co.’s experimental drug effectively treats ulcerative colitis and Crohn’s disease, inflammatory bowel diseases that affect as many as 1.4 million Americans, two studies found.
Among patients with ulcerative colitis who took Takeda’s intravenous drip vedolizumab for a year, at least 40 percent had a temporary end to symptoms, compared with those who took placebo for the same period, according to results published today in the New England Journal of Medicine. A separate study found the drug helped Crohn’s patients reach remission after a year of treatment, compared with those on placebo.